Nisarfathima Kazimuddin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nisarfathima Kazimuddin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Irfan Waheed
Department of Medicine, University of Kentucky, College of Medicine, Bowling Green, Kentucky, USA
2 shared publications - Muhammad Altaf Ahmed
Department of Medicine, University of Kentucky, College of Medicine, Bowling Green, Kentucky, USA
2 shared publications - Rodney T. Steff
Department of Medicine, University of Kentucky, College of Medicine, Bowling Green, Kentucky, USA
2 shared publications - Suman Mbbs Kadariya
Department of Medicine, KIST Medical College and Teaching Hospital, Imadol, Lalitpur, Nepal
2 shared publications - Tahir Muhammad Abdullah Khan
Department of Medicine, University of Kentucky, College of Medicine, Bowling Green, Kentucky, USA
2 shared publications - Yub Raj Sedhai
Department of Medicine, University of Kentucky, College of Medicine, Bowling Green, Kentucky, USA
2 shared publications
Latest Publications
- Open Access
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4467-4475
Endobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis
Background: Chronic obstructive pulmonary disease (COPD) causes permanent lung damage and is a global health issue. Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr valves has increased COPD treatment choices for individuals with persistent symptoms despite maximal drug therapy. Objectives: This systematic review and meta-analysis evaluated available Zephyr valve data in severe emphysema patients. Data and methods: We searched Cochrane, PubMed, Google Scholar, Lilacs, and Science Direct extensively and included eight randomized control trials (RCTs). Results: This meta-analysis comprises 1083 patients 669 Zephyr valve-treated and 414 control. The mean difference in 6-minute walking distance was 37.53 meters (95% CI: 22.14–52.90, P < 0.001). Statistically significant improvements were also observed in FEV1 predicted percentage (mean difference: 13.64, 95% CI: 8.51–18.77, P < 0.001) and BODE index change (mean difference: −0.79, 95% CI: −1.33 to 0.26, P < 0.05), mMRC dyspnea scale (mean difference: −0.27, 95% CI: −0.55 to 0.02, P < 0.01) and residual volume (mean difference: −0.14, 95% CI: −0.64 to 0.35, P < 0.01). The quality of life measured by SGRQ also improved significantly (mean difference: −6.69, 95% CI: −9.69, −4.23, P < 0.001). While COPD exacerbation rates (OR:1.41, 95% CI: 0.87–2.30, P > 0.05) and pneumonia rates (OR: 1.72, 95% CI: 0.7–4.23, P > 0.05) were similar between valve and control groups, pneumothorax risk was significantly higher in the treatment arm (OR: 11.06, 95% CI: 4.10–29.80, P < 0.001). However, there was no significant difference in all-cause mortality between the groups (OR: 1.69; 95% CI: 0.53–5.38, P > 0.38). Conclusion: Zephyr valves may improve lung function, exercise capacity, and quality of life in patients suffering from severe emphysema. However, the increased risk of pneumothorax requires careful patient selection and rigorous post-intervention monitoring.
- 16 June 2025
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 87 (7) , 4467-4475
Open AccessEndobronchial Zephyr valves for bronchoscopic lung volume reduction for severe emphysema: a systematic review and meta-analysis
Background: Chronic obstructive pulmonary disease (COPD) causes permanent lung damage and is a global health issue. Bronchoscopic Lung Volume Reduction (BLVR) with Zephyr valves has increased COPD treatment choices for individuals with persistent symptoms despite maximal drug therapy. Objectives: This systematic review and meta-analysis evaluated available Zephyr valve data in severe emphysema patients. Data and methods: We searched Cochrane, PubMed, Google Scholar, Lilacs, and Science Direct extensively and included eight randomized control trials (RCTs). Results: This meta-analysis comprises 1083 patients 669 Zephyr valve-treated and 414 control. The mean difference in 6-minute walking distance was 37.53 meters (95% CI: 22.14–52.90, P < 0.001). Statistically significant improvements were also observed in FEV1 predicted percentage (mean difference: 13.64, 95% CI: 8.51–18.77, P < 0.001) and BODE index change (mean difference: −0.79, 95% CI: −1.33 to 0.26, P < 0.05), mMRC dyspnea scale (mean difference: −0.27, 95% CI: −0.55 to 0.02, P < 0.01) and residual volume (mean difference: −0.14, 95% CI: −0.64 to 0.35, P < 0.01). The quality of life measured by SGRQ also improved significantly (mean difference: −6.69, 95% CI: −9.69, −4.23, P < 0.001). While COPD exacerbation rates (OR:1.41, 95% CI: 0.87–2.30, P > 0.05) and pneumonia rates (OR: 1.72, 95% CI: 0.7–4.23, P > 0.05) were similar between valve and control groups, pneumothorax risk was significantly higher in the treatment arm (OR: 11.06, 95% CI: 4.10–29.80, P < 0.001). However, there was no significant difference in all-cause mortality between the groups (OR: 1.69; 95% CI: 0.53–5.38, P > 0.38). Conclusion: Zephyr valves may improve lung function, exercise capacity, and quality of life in patients suffering from severe emphysema. However, the increased risk of pneumothorax requires careful patient selection and rigorous post-intervention monitoring.
- Open Access
- 28 December 2024
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 53, 102161
Primary malignant melanoma of the lung; a case report and literature review
- 28 December 2024
- Published by Elsevier in Respiratory Medicine Case Reports
- Vol. 53, 102161
Open AccessPrimary malignant melanoma of the lung; a case report and literature review